#1 Clinical Trials Search in Europe

Toripalimab

Toripalimab, a promising immunotherapy drug, is currently being studied in various clinical trials for its effectiveness in treating different types of cancer. These trials aim to evaluate how Toripalimab, either alone or in combination with other treatments, can improve outcomes for patients with conditions such as lung cancer, head and neck cancers, and cervical cancer. This article summarizes key information about ongoing Toripalimab clinical trials and their potential impact on cancer treatment.

Table of Contents

What is Toripalimab?

Toripalimab is a type of cancer drug known as an immunotherapy. It’s also referred to by other names such as JS001, TAB001, or TORIPALIMAB INJECTION (JS001)[1]. This medication is designed to help your body’s immune system fight cancer cells more effectively.

How Does Toripalimab Work?

Toripalimab belongs to a class of drugs called PD-1 inhibitors. PD-1 is a protein on immune cells that acts like a “brake” to prevent them from attacking other cells. Some cancer cells can use this brake to avoid being destroyed by the immune system. Toripalimab works by blocking this brake, allowing the immune system to recognize and attack cancer cells more effectively[1].

Cancers Treated with Toripalimab

Toripalimab is being studied for the treatment of several types of cancer, including:

  • Non-small Cell Lung Cancer (NSCLC): This is the most common type of lung cancer[2][1].
  • Small Cell Lung Cancer (SCLC): A less common but more aggressive form of lung cancer[3].
  • Nasopharyngeal Carcinoma (NPC): A type of cancer that starts in the nasopharynx, the upper part of the throat behind the nose[4].
  • Mucosal Melanoma: A rare type of melanoma that occurs on mucous membranes[5].
  • Breast Cancer: Specifically, HR-positive, HER2-negative breast cancer[6].
  • Laryngeal and Hypopharyngeal Cancer: Cancers that affect the voice box (larynx) and the lower part of the throat (hypopharynx)[7].

Toripalimab in Clinical Trials

Toripalimab is currently being studied in several clinical trials to determine its effectiveness in treating various cancers. These trials are investigating:

  • Toripalimab combined with chemotherapy for advanced NSCLC[2][1].
  • Toripalimab with chemotherapy for extensive-stage small cell lung cancer[3].
  • Toripalimab combined with other targeted therapies, such as axitinib for mucosal melanoma[5].
  • Toripalimab with radiotherapy and chemotherapy for nasopharyngeal carcinoma[4].
  • Toripalimab in combination with stereotactic body radiation therapy (SBRT) for NSCLC[8].

Administration and Dosage

Toripalimab is typically administered as an intravenous (IV) infusion. The common dosage is 240mg every 3 weeks (Q3W)[2][1]. However, the exact dosage and schedule may vary depending on the specific cancer type and treatment plan. In some trials, it’s given for up to 2 years or until disease progression or intolerable side effects occur[3].

Potential Side Effects

As with any medication, Toripalimab can cause side effects. These are carefully monitored in clinical trials. Common side effects of immunotherapy drugs like Toripalimab may include fatigue, skin rashes, and diarrhea. More serious side effects can occur but are less common. It’s important to discuss potential side effects with your healthcare provider[2][1].

Future Prospects

Researchers are exploring new ways to use Toripalimab, including:

  • As a maintenance therapy after initial treatment for small cell lung cancer[9].
  • In combination with radiation therapy for various cancers[8][7].
  • As part of neoadjuvant therapy (treatment given before surgery) for breast cancer[6].

These ongoing studies aim to determine the most effective ways to use Toripalimab and identify which patients are most likely to benefit from this treatment.

Cancer Type Trial Phase Combination Therapy Primary Outcome Measures
Non-small cell lung cancer Not specified SBRT (Stereotactic Body Radiation Therapy) Major pathological remission rate
Laryngeal/Hypopharyngeal Cancer Not specified Induction chemotherapy, radiotherapy Progression-free survival
Small cell lung cancer III Anlotinib (maintenance) Progression-free survival, Overall survival
Head and neck squamous cell carcinoma II Maintenance therapy after first-line treatment 2-year progression-free survival
Oral squamous cell carcinoma II Nimotuzumab (neoadjuvant) Major Pathologic response rate
Cervical cancer II Chemoradiotherapy 2-year progression-free survival
Small cell lung cancer (limited stage) II Consolidation after chemoradiotherapy Progression-free survival
Nasopharyngeal carcinoma (recurrent) II Concurrent chemoradiotherapy Overall survival
Nasopharyngeal carcinoma (advanced) Not specified Neoadjuvant chemotherapy Complete Response rate

FAQ

  • What is Toripalimab? Toripalimab is a type of immunotherapy drug known as a PD-1 inhibitor. It works by helping the body's immune system recognize and attack cancer cells more effectively.
  • What types of cancer are being studied with Toripalimab? Clinical trials are exploring Toripalimab's effectiveness in various cancers, including non-small cell lung cancer, small cell lung cancer, head and neck cancers, cervical cancer, and nasopharyngeal carcinoma.
  • How is Toripalimab administered in these trials? In most trials, Toripalimab is administered intravenously, typically at a dose of 240mg every 3 weeks. The duration and frequency may vary depending on the specific trial and treatment plan.
  • What are some potential side effects of Toripalimab? As with other immunotherapy drugs, Toripalimab may cause immune-related side effects. These can vary in severity and may include fatigue, skin reactions, and changes in hormone levels. Specific side effects are being closely monitored in each trial.
  • How long do these clinical trials typically last? The duration of clinical trials varies, but many of the Toripalimab studies are following patients for several years to assess long-term outcomes such as progression-free survival and overall survival.

Ongoing Clinical Trials on Toripalimab

  • Study on Toripalimab and Tifcemalimab for Patients with Limited-Stage Small Cell Lung Cancer After Chemoradiotherapy

    Recruiting

    1 1
    Investigated drugs:
    Belgium France Germany Italy The Netherlands Poland +2

  • Study of toripalimab, cisplatin and gemcitabine combination as first treatment for patients with recurrent or metastatic nasopharyngeal cancer

    Not yet recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy

  • Study Comparing Toripalimab and Lenvatinib with Placebo and Lenvatinib for First-Line Treatment in Patients with Advanced Liver Cancer

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Italy Poland

Glossary

  • PD-1 inhibitor: A type of drug that blocks a protein called PD-1 on certain immune cells, helping the immune system recognize and attack cancer cells more effectively.
  • Neoadjuvant therapy: Treatment given before the main treatment, usually to shrink a tumor before surgery or radiation therapy.
  • Chemoradiotherapy: A treatment that combines chemotherapy (using drugs to kill cancer cells) with radiation therapy.
  • Progression-free survival (PFS): The length of time during and after treatment that a patient lives with cancer without it getting worse.
  • Overall survival (OS): The length of time from the start of treatment or diagnosis that patients are still alive.
  • Objective response rate (ORR): The proportion of patients whose cancer shrinks or disappears after treatment.
  • RECIST criteria: Response Evaluation Criteria in Solid Tumors, a standard way to measure how well a cancer patient responds to treatment.
  • Adverse events: Unexpected medical problems that happen during treatment with a drug or other therapy.
  • Quality of life (QoL): A measure of a patient's general well-being and satisfaction with life in relation to their health and treatment.
  • Immunotherapy: A type of cancer treatment that helps the body's immune system fight cancer.

References

  1. https://clinicaltrials.gov/study/NCT03856411
  2. https://clinicaltrials.gov/study/NCT03924050
  3. https://clinicaltrials.gov/study/NCT04012606
  4. https://clinicaltrials.gov/study/NCT06712888
  5. https://clinicaltrials.gov/study/NCT04180995
  6. https://clinicaltrials.gov/study/NCT06705127
  7. https://clinicaltrials.gov/study/NCT05420597
  8. https://clinicaltrials.gov/study/NCT06293690
  9. https://clinicaltrials.gov/study/NCT06441344